TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11289288
Drug: Topical 0.3
Normalized name: triclosan topical 0.3% topical bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.3 percent nifedipine and 1.5 percent lidocaine ointment every 12 hours for two weeks
Study: 11289288
Drug: Topical 1.5
Normalized name: phenol topical 1.5% topical liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.5 percent lidocaine ointment
Study: 9879778
Drug: Paclitaxel 210
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 210 mg/m2 as a 3 hour infusion every three weeks until toxicity or progression
Study: 6102797
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or low dosages of antipsychotics (PLD)
Study: 6102797
Drug: High conventional
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High conventional dosages of antipsychotics (HCD)
Study: 27011294
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg fish oil supplements daily containing 120 mg DHA and 180 mg EPA
Study: 23196671
Drug: Hass avocado
Normalized name: Avocado
DrugBank: Avocado (DB10504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hass avocado (68 g) with hamburger
Study: 23196671
Drug: Hamburger alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hamburger alone (250 g)
Study: 12547847
Drug: Acarbose (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (titrated up to 100 mg b.i.d.)
Study: 11180022
Drug: Cetrorelix 1
Normalized name: cetrorelix 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 1 mg
Study: 11180022
Drug: Cetrorelix 3
Normalized name: cetrorelix 3 mg subcutaneous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix 3 mg
Study: 11180022
Drug: Cetrorelix 5
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetrorelix 5 mg
Study: 1726004
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 to 6 mg once daily)
Study: 1726004
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 to 50 mg once daily)
Study: 6354408
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base and metronidazole (oral)
Study: 26908016
Drug: Management strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management strategies involving drug discontinuation only (37%)
Study: 26908016
Drug: Management strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management strategies involving drug discontinuation with transfusion of red cell concentrates (38%)
Study: 26908016
Drug: Management strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management strategies involving drug discontinuation with transfusion of plasma (23%)
Study: 26908016
Drug: Warfarin management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin management
Study: 22885247
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg THC
Study: 22885247
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg THC
Study: 22885247
Drug: THC (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (all doses)
Study: 6342643
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 100 micrograms
Study: 6342643
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (various doses)
Study: 27098817
Drug: CET as
Normalized name: CET
DrugBank: Cefalotin (DB00456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CET as group therapy
Study: 20386062
Drug: Creative arts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creative arts therapy (CAT)
Study: 18714203
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (body stroking and passive limb movements for three, 15-minute periods per day for 5 days)
Study: 18714203
Drug: Standard nursery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nursery care without massage therapy
Study: 10408495
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy with cyclophosphamide, methotrexate, and fluorouracil
Study: 8911372
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine dermal patches postauricularly
Study: 1875230
Drug: Cefotetan (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (total dose, 20 g)
Study: 1875230
Drug: Clindamycin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (total dose, 12 g) plus Amikacin (total dose, 5 g)
Study: 6897369
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (FAC: fluorouracil, doxorubicin, and cyclophosphamide) with delays of less than 10 weeks
Study: 6897369
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (FAC) with delays of 10-13 weeks
Study: 6897369
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (FAC) with delays of 14-17 weeks
Study: 6897369
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (FAC) with delays of greater than or equal to 18 weeks
Study: 29921393
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve block (cFNB) with 0.375% ropivacaine hydrochloride, 20 mL loading dose
Study: 29921393
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) with fentanyl, 0.05 mg loading dose
Study: 24025033
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy combined with functional strength training
Study: 24025033
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy combined with movement performance therapy
Study: 12226016
Drug: Salmeterol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (25 micro g, two puffs bid for 6 weeks)
Study: 9513753
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic hormone (ANH)
Study: 2518874
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.m.
Study: 21748770
Drug: Rosiglitazone alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone alone (4 mg twice-daily)
Study: 21748770
Drug: Rosiglitazone and
Normalized name: Rosiglitazone and Glimepiride Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone and metformin (4 mg rosiglitazone and 500 mg metformin twice-daily)
Study: 21748770
Drug: Rosiglitazone and
Normalized name: Rosiglitazone and Glimepiride Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone and losartan (4 mg rosiglitazone and 50 mg losartan once-daily)
Study: 14625121
Drug: Oral 17beta‐E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17beta‐E2 + NETA for 3 months
Study: 14625121
Drug: Transdermal 17beta‐E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐E2 + MPA for 3 months
Study: 14625121
Drug: Transdermal 17beta‐E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐E2 + MPA for 12 months
Study: 1593561
Drug: Hygroscopic cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygroscopic cervical dilators and Intracervical prostaglandin E2 (PGE2) gel
Study: 2934579
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with flutamide and LHRH agonist (or orchiectomy)
Study: 31439956
Drug: Steroids (n=77)
Normalized name: N-Vanillylnonamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (n=77)
Study: 25352732
Drug: Four tablets
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four tablets at full dose
Study: 25352732
Drug: Two softgels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two softgels at full dose
Study: 25352732
Drug: One softgel
Normalized name: Stuart One Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: One softgel at half-dose
Study: 25352732
Drug: Zinc absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc absorption
Study: 22967121
Drug: Levofloxacin/amoxicillin/esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin/amoxicillin/esomeprazole
Study: 9150331
Drug: Hospital therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital therapy
Study: 8398529
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and droperidol
Study: 2943643
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin K 2165
Study: 26547291
Drug: Evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 140 mg biweekly (Q2W) or 420 mg monthly (QM)
Study: 24767519
Drug: Protocol-directed physical
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol-directed physical therapy (pdPT)
Study: 24767519
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (ST)
Study: 18480036
Drug: Percentage format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percentage format (e.g., 12%)
Study: 18480036
Drug: Frequency format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency format (e.g., 12 in 100)
Study: 18480036
Drug: 1-in-n format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-in-n format (e.g., 1 in 8)
Study: 15900006
Drug: Meta-analyses (limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meta-analyses (limited to studies addressing treatment effects)
Study: 10029478
Drug: Subperiosteal nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subperiosteal nasal floor augmentation with Surgicel
Study: 8659717
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/mL
Study: 8659717
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/mL plus lidocaine 10 mg/mL
Study: 8659717
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg/mL plus lidocaine 20 mg/mL
Study: 1794158
Drug: Clomipramine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 150 mg/day administered at noon
Study: 1794158
Drug: Clomipramine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 150 mg/day administered at morning or before bedtime
Study: 1794158
Drug: Clomipramine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine administered three times a day by traditional, equally divided doses
Study: 6363078
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg (N10)
Study: 6363078
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg (N20)
Study: 26922537
Drug: Atorvastatin 40mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40mg/d
Study: 26922537
Drug: Atorvastatin 40mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40mg/d + Ezetimibe 10mg/d
Study: 23668824
Drug: Triclosan-containing toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triclosan-containing toothpaste (3000 μg/mL TCS)
Study: 17406798
Drug: Paclitaxel-containing radiochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel-containing radiochemotherapy (paclitaxel 25-35 mg/m² twice weekly)
Study: 17406798
Drug: Radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation treatment administered to a total dose of 45-60 Gy
Study: 14695786
Drug: PEG‐IFN (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN (0.5 microg/body weight/week) and ribavirin (1,000 mg-1,200 mg/daily) for 48 weeks
Study: 9208361
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg) administered alone
Study: 9208361
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg) administered after ranitidine treatment
Study: 9208361
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg) with cola beverage
Study: 9208361
Drug: Ranitidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine treatment (gastric pH at least 6.0)
Study: 8119049
Drug: Theophylline target
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline target concentration of 10 mg/L
Study: 8119049
Drug: Theophylline target
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline target concentration of 20 mg/L
Study: 23881309
Drug: internet-delivered acceptance
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered acceptance and commitment therapy (iACT)
Study: 23237436
Drug: ω-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 PUFA treatment (1 g/day for 6 months)
Study: 20354834
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1,200 mg d(‐1) for 8 days prior to exercise trial and 600 mg on the day of exercise trial
Study: 18622600
Drug: Brain natriuretic
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain natriuretic peptide (BNP) infusion at 16.2 pmol/min for 30 min
Study: 18622600
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at 16.2 pmol/min for 30 min
Study: 12598065
Drug: Ximelagatran (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (15, 30 or 60 mg)
Study: 12598065
Drug: r-hirudin (intravenous)
Normalized name: R-hirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: r-hirudin (intravenous)
Study: 12598065
Drug: Enoxaparin (subcutaneous)
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (subcutaneous)
Study: 12851531
Drug: Ximelagatran (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran (60 mg)
Study: 9708720
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 0.050% nasal spray, 50 microg, 4 times daily for 2 weeks
Study: 9708720
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate 0.075% nasal spray, 75 microg, 4 times daily for 2 weeks
Study: 359398
Drug: Atenolol (ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (ICI 66082) 100 mg daily for 30 days
Study: 359398
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 30 days
Study: 28510350
Drug: Nebulised hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised hypertonic saline (administered 38.7%–74.7% of the time in Ward A and Ward B)
Study: 28510350
Drug: Nebulised hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised hypertonic saline (administered infrequently at 6.7% in Ward C)
Study: 9001307
Drug: Inhaled indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled indomethacin (3 mg/m2 body surface area)
Study: 8515850
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg i.m. every 6 hours)
Study: 8515850
Drug: Buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.3 mg i.m. every 12 hours)
Study: 2877912
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg h.s.
Study: 30982861
Drug: Glucoraphanin-rich broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucoraphanin-rich broccoli soup (300 mL weekly)
Study: 30982861
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard broccoli soup, 300 mL weekly)
Study: 26486855
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (Xeomin, Merz, Germany; 50 U/1 mL at each fat pad)
Study: 26486855
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% normal saline, 1 mL at each fat pad)
Study: 23717976
Drug: Compound Xiatianwu
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xiatianwu tablets (2 tablets each time, 3 times/day for 3 months)
Study: 23717976
Drug: Xiatianwu group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiatianwu group (not specified dosage or duration)
Study: 2659299
Drug: Traditional Dressing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Dressing Treatment (TDT)
Study: 28477375
Drug: l-tyrosine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-tyrosine (150 mg kg-1)
Study: 26134076
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (Zn sulfate 70 mg daily for 16 weeks)
Study: 26134076
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsules containing wheat starch with no added Zn)
Study: 26134076
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with Zinc supplementation (Zn sulfate 70 mg daily for 16 weeks)
Study: 26134076
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with Placebo (identical capsules containing wheat starch with no added Zn)
Study: 23343453
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics other than clozapine (NTR group)
Study: 16920550
Drug: Acetaminophen-codeine
Normalized name: acetaminophen-codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen-codeine
Study: 1587959
Drug: bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (400 mg daily)
Study: 1587959
Drug: simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (20 mg daily)
Study: 27716422
Drug: YXBCM01 granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: YXBCM01 granule 5.5 g twice daily for 12 weeks
Study: 27716422
Drug: Placebo granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules 5.5 g twice daily for 12 weeks
Study: 22898340
Drug: Cardiac shock
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac shock wave therapy (CSWT) performed 3 times within 3 months (Group A, n = 20)
Study: 22898340
Drug: Cardiac shock
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac shock wave therapy (CSWT) performed 3 sessions/week for 1 month (Group B, n = 21)
Study: 22898340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 14) received only medical therapy
Study: 18060588
Drug: 750 mL
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mL orange juice (containing 0.545 g PB)
Study: 18060588
Drug: PB supplement
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB supplement (0.545 g PB dissolved in 750 mL apple juice)
Study: 18060588
Drug: 750 mL
Normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mL apple juice (control)
Study: 14984384
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid plus paracetamol plus caffeine
Study: 3237227
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg phenobarbital
Study: 3237227
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg phenobarbital
Study: 30450925
Drug: β‐blocker uptitration
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐blocker uptitration
Study: 26900091
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with cetuximab (Arm B)
Study: 26900091
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy without cetuximab (Arm A)
Study: 16758263
Drug: Itraconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (100 mg, first dose 200 mg)
Study: 20150523
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg)
Study: 16758263
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of itraconazole and gemfibrozil
Study: 12890944
Drug: Postnatal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postnatal steroid therapy
Study: 12890944
Drug: Guidelines for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines for steroid use by the American Academy of Pediatrics and the Canadian Paediatric Society
Study: 29177955
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate 6 g daily (N = 17)
Study: 27053380
Drug: Maternal LCPUFA
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal LCPUFA supplementation (1020 mg DHA plus 180 mg EPA/d)
Study: 20223994
Drug: Exercise plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise plus volume infusion (dextran)
Study: 20223994
Drug: Volume infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volume infusion alone (dextran)
Study: 11952026
Drug: IM ertapenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM ertapenem 1 g once daily